An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab

To the Editor: Dupilumab has revolutionized the management of patients with moderate-to-severe atopic dermatitis (AD). Despite its superior efficacy over prior treatments, nonresponse to dupilumab is not infrequent. 1 Linder C. Shourick J. Touhouche A.T. et al. Analysis of non-responders to dupilumab in clinical practice: a cohort study. J Eur Acad Dermatol Venereol. 2021; 35: e192-e194 Crossref PubMed Scopus (4) Google Scholar Thus, additional novel therapeutic options need to be developed. Abrocitinib, an oral Janus kinase 1-selective inhibitor, has been clinically investigated to treat moderate-to-severe AD 2 Silverberg J.I. Simpson E.L. Thyssen J.P. et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020; 156: 863-873 Crossref PubMed Scopus (199) Google Scholar and has been approved for treating moderate-to-severe AD in several countries. 3 Deeks E.D. Duggan S. Abrocitinib: first approval. Drugs. 2021; 81: 2149-2157 Crossref PubMed Scopus (24) Google Scholar ,4 U.SFDA approves Pfizer's CIBINQO® (abrocitinib) for adults with moderate-to-severe atopic dermatitis-Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adultsDate accessed: April 5, 2022 Google Scholar A clinical trial has demonstrated good outcomes in patients who were switched from dupilumab to abrocitinib for an inadequate response, 5 Shi V.Y. Bhutani T. Fonacier L. et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022; 87: 351-358 Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar however, there is a lack of data on the outcomes and safety profile of such a switch in the real-world. To address this gap, we assessed the efficacy and safety of this treatment option in the real-world settings.